Can Personalized Optimization of Acid Suppression Dosage and Duration Improve the Management of Artificial Ulcers After Gastric Endoscopic Submucosal Dissection?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Han Y, Zhou L, Hu Y, Ding X, Long H, Liu F
. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study. J Gastroenterol. 2023; 58(12):1167-1177.
DOI: 10.1007/s00535-023-02042-2.
View
2.
Hamada S, Ihara E, Ikeda H, Muta K, Ogino H, Chinen T
. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease. Digestion. 2019; 102(2):197-204.
DOI: 10.1159/000503340.
View
3.
Kuribayashi S, Nakamura F, Motegi S, Hara K, Hosaka H, Sekiguchi A
. Prevalence and risk factors for medication-refractory reflux esophagitis in patients with systemic sclerosis in Japan. J Gastroenterol. 2024; 59(3):179-186.
DOI: 10.1007/s00535-024-02076-0.
View
4.
Chen L, Jiang D, Hu D, Cui X
. Comparison of vonoprazan and proton pump inhibitors for the treatment of gastric endoscopic submucosal dissection-induced ulcer: an updated systematic review and meta-analysis. BMC Gastroenterol. 2024; 24(1):110.
PMC: 10943859.
DOI: 10.1186/s12876-024-03198-8.
View
5.
Tian L, Xiang D, Yue F, Li R, Zhou Y
. Efficacy and safety of vonoprazan versus proton pump inhibitors in the treatment of peptic ulcer disease: a systematic review and network meta-analysis for randomized controlled trails. Front Nutr. 2024; 11:1436993.
PMC: 11412081.
DOI: 10.3389/fnut.2024.1436993.
View